GlassScriptPhysician profile
Mauricio Orrego
NPI 1376502617
$2,355.76
in general payments reported to CMS, 2019-2025
20 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $1,142 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.20 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $418.36 | 2024-2025 | Livdelzi, Vemlidy |
| Ipsen Biopharmaceuticals, INC | $351.78 | 2024-2025 | Iqirvo, Bylvay |
| Boston Scientific Corporation | $288.86 | 2024-2025 | Therasphere Administration Set, Therasphere Y90 Glass Microspheres 10 Gbq |
| Mallinckrodt Hospital Products INC. | $217.93 | 2024-2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.08 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $137.48 | 2023-2025 | Prevymis |
| Madrigal Pharmaceuticals | $135.80 | 2024-2025 | Resmetirom, Rezdiffra |
| Exact Sciences Corporation | $116.13 | 2024 | |
| Veloxis Pharmaceuticals, INC. | $100.93 | 2023-2024 | Envarsus |
| Paragonix Technologies, INC. | $67.89 | 2024 | Liverguard, Sherpapak, Pancreaspak |
| Takeda Pharmaceuticals U.S.A., INC. | $67.71 | 2023-2025 | Livtencity |
| Intercept Pharmaceuticals, INC. | $49.66 | 2023-2024 | Ocaliva |
| Abbvie INC. | $46.21 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $41.41 | 2024 | |
| Orphalan INC | $38.40 | 2024-2025 | Cuvrior |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.60 | 2025 | Ozempic |
| Lilly USA, LLC | $33.29 | 2025 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $27.77 | 2025 | Givlaari |
| Alexion Pharmaceuticals, INC. | $19.76 | 2023 | Ultomiris |
| Kci USA, INC. | $19.71 | 2023 | Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Orrego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.